ClinicalTrials.gg
CompletedNCT03777254Updated Apr 27, 2021

Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration

A Phase 1 interventional study of RC28-E in Neovascular Age-related Macular Degeneration, sponsored by RemeGen Co., Ltd.. Completed at 1 site in China. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-04-27.

Sponsored by RemeGen Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
50 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 106 studies in Macular Degeneration with a site in China — 36 open to participants now, 43 under way, 9 of them phase 3. Macular Degeneration · China.

Enrollment
79th of 91
12 · median 62
Started
2019
with 6 others
Phase 1
20 of 106
5 open now
Registered
31st of 106
by date
Lead sponsor
3 of 106
RemeGen Co., Ltd.

Among the 106 studies in Macular Degeneration with a site in China, this one is the 79th largest by enrollment of the 91 interventional ones that give a count, is one of 7 that started in 2019, is one of 20 in phase 1, and was the 31st registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

36 of the 106 studies in Macular Degeneration with a site in China are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 50 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Macular Degeneration with a site in China, or all of them as a file.
02

Study summary

The purpose of this first-in-human study is to evaluate the safety, tolerability and pharmacokinetics of single intravitreous injections,single ascending doses, of RC28-E(a chimeric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2) in subjects with wet age-related macular degeneration (wAMD).

Read the detailed description

This is an open-label, non-randomized,double-center phase 1 study evaluating pharmacokinetics, safety and tolerability of single intravitreal injections of RC28-E in the patients with AMD.RC28-E is recombinant dual decoy receptor IgG1 Fc-fusion protein,can block VEGF-A and FGF-2. In preclinical studies suggested that RC28-E might be more effective in inhibiting pathological angiogenesis than other VEGF antagonists on CNV. Every subject will only accept one dose. In addition to safety and preliminary efficacy, pharmacokinetics and immunogenicity of RC28-E will be evaluated as well.

03

Conditions studied

  • Neovascular Age-related Macular Degeneration
04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients or their legal representative signed ;
  2. Aged 50 years to 80 years, male or female;
  3. Best corrected VA for the studied eye≥34 letters, ≤73 letters(By ETDRS chart);
  4. With choroidal neovascular (CNV) lesions secondary to neovascular AMD;
  5. If both eyes meet the criteria, severe illness eye will be selected; if both eyes are the same, the right eye will be selected as the study eye.

Exclusion criteria

Exclusion Criteria:

  1. History of any vitreous hemorrhage with 2 months prior to screening;
  2. Presence of scar, fibrosis or atrophy in central foveal of the study eye;
  3. Significant refractive media opacity, including cataract, may interfere with visual assessment;
  4. The studied eye suffered pseudoexfoliation syndrome, central retinal vein occlusion, intraocular hemorrhage resulting in decreased vision, rhegmatogenous retinal detachment, macular hole, choroidal neovascularization (CNV) for any reason other than AMD (such as fundus angioid streaks, ocular histoplasmosis, pathologic myopia, trauma);
  5. Afferent pupillary defect(APD);
  6. The intraocular pressure is higher than 25mmHg despite medication treatment;
  7. Active infectious conjunctivitis, keratitis, scleritis, uveitis and endophthalmitis;
  8. Best corrected VA for the studied eye≤19 letters(By ETDRS chart);
  9. Topical or grid photocoagulation within 3 months before screening;
  10. Uncontrolled diabetes mellitus(fast glucose level≥7.0 mmol/L or ≥11.1 mmol/L 2h after meal;
  11. The studied eye received any intraocular surgery or laser treatment (such as macular translocation surgery, glaucoma filtering surgery, transpupillary thermotherapy, foveal photocoagulation surgery, vitrectomy, optic neurotomy, optic nerve sheath fenestration; But cataract surgery, verteporfin photodynamic therapy, Nd:YAG laser posterior capsulotomy more than 3 months before screening can be selected;
  12. Any eye or whole body received anti-angiogenic drug such as pegaptanib, Aflibercept, Ranibizumab, Bevacizumab,conbercept within 3 months before baseline visit;
  13. Any eye received intraocular injection of drugs (such as triamcinolone acetonide) within 3 months before screening, or periocular injection of corticosteroid drugs within 1 months before screening;
  14. Allergic to sodium fluorescein, indocyanine green, therapeutic or diagnostic protein products, and allergic ≥2 drugs and/or non-drugs, or with current allergic diseases;
  15. With surgery within one month prior to enrollment, or with unhealed wound, ulcer, fracture at present;
  16. No lens (excluding intraocular lens);
  17. Uncontrolled hypertension(defined as those who received the best treatment regimen, >180 mmHg systolic was measured once, >160 mmHg systolic or > 100 mmHg diastolic was measured twice in succession);
  18. With a history of myocardial infarction within 6 months before screening;
  19. With activity disseminated intravascular coagulation and significant bleeding tendency prior to screening; Using anticoagulants or antiplatelet aggregation drugs in addition to aspirin/NSAIDs within 14 days before screening;
  20. Any uncontrolled clinical disease (such as severe mental, neurological, cardiovascular, respiratory and other systemic diseases and malignant tumors);
  21. Pregnant (blood pregnancy test positive) and lactating women and patients who cannot take effective (such as intrauterine devices, acyeterion, condoms, etc.) between study period or 30 days after visit;
  22. Patients who participated in or were currently attending other clinical studies within 30 days before screening;
  23. The patients is considered unsuitable for enrollment by investigator. "
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    RC28-E

    "·Experimental:RC28-E 0.25mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E * Experimental: RC28-E 0.5mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E * Experimental: RC28-E 1.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E * Experimental: RC28-E 2.0mg Injection:single Intravitreal Injection Intervention: Biological: RC28-E"

    Biological: RC28-E

Interventions

  • BiologicalRC28-E

    RC28-E intravitreous injection 50ul

    Also known as: RC28-E is a chimeric decoy receptor trap fusion protein by dual blockage of VEGF and FGF-2.

06

What researchers measure

Primary outcomes

  1. Incidence of ocular and systemic adverse events and serious adverse events which are related to RC28-E

    Time frame: 42 days

Secondary outcomes

  1. Area under the plasma concentration-time curve(AUC)

    Time frame: 42 days

  2. Maximum observed maximum plasma concentration (Cmax)

    Time frame: 42 days

  3. Time to reach the maximum observed plasma concentration (Tmax)

    Time frame: 42 days

  4. T1/2(Terminal phase half life after single dose)

    Time frame: 42 days

  5. Change in Best Corrected Visual Acuity (BCVA) from baseline

    Time frame: 42 days

  6. Change in Central Retinal Thickness(CRT)from baseline

    Time frame: 42 days

07

Study locations

1 site
  • Beijing Tongren Hospital .Cmu
    Beijing, 100730, China
08

References and documents

Publications

  • Kou X, Sun Y, Li S, Bian W, Liu Z, Zhang D, Jiang J. Pharmacology Study of the Multiple Angiogenesis Inhibitor RC28-E on Anti-Fibrosis in a Chemically Induced Lung Injury Model. Biomolecules. 2019 Oct 24;9(11):644. doi: 10.3390/biom9110644. PubMed 31652997 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2019 to primary completion in Aug 2019, 7 months.

Of 60 industry-sponsored phase 1 interventional studies under Macular Degeneration, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 27. This study's 7 months is below that.

Counting every sponsor, half of 75 studies reached it within 18 months; a quarter within 10 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2018
First posted
Dec 17, 2018
StartActual
Jan 7, 2019
Primary completionActual
Aug 20, 2019
CompletionActual
Aug 20, 2019
Last update
Apr 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03777254
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Dec 17, 2018
Start date
Jan 7, 2019
Primary completion
Aug 20, 2019
Completion
Aug 20, 2019
Last update
Apr 27, 2021

Study contacts

wenbin wei
principal investigator · BEIJING TONGREN HOSPITAL.CMU

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RC28-E protein

Start the discussion